Abstract
Moderate-to-severe ulcerative colitis can be effectively treated with JAK-1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune-mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug-induced is uncertain.